<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autoimmunity and immune dysregulation in inborn error of immunity/primary immunodeficiency disorders</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autoimmunity and immune dysregulation in inborn error of immunity/primary immunodeficiency disorders</h1>
<div class="graphic"><div class="figure"><div class="ttl">Autoimmunity and immune dysregulation in inborn error of immunity/primary immunodeficiency disorders</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td class="subtitle1">IEI/PID/syndrome<br/> (in approximate order of prevalence)</td> <td class="subtitle1">Estimated prevalence</td> <td class="subtitle1">IUIS IEI <span class="nowrap_whitespace">classification<sup>[1]</sup></span></td> <td class="subtitle1">Hallmarks<br/> (of the IEI)</td> <td class="subtitle1">Immunodeficiency features</td> <td class="subtitle1">Possible manifestations of autoimmunity and/or immune dysregulation</td> <td class="subtitle1">Suspected predominant mechanism(s) of autoimmunity or immune <span class="nowrap_whitespace">dysregulation<sup>[2-5]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Selective IgA deficiency</td> <td>1 to 3:1000</td> <td>Predominantly antibody deficiencies</td> <td> <ul> <li>Allergies; may precede CVID or have positive family history</li> </ul> </td> <td>Asymptomatic or recurrent sinopulmonary bacterial infections</td> <td> <ul> <li>Endocrinopathies</li> <li>Cytopenia</li> </ul> </td> <td> <ul> <li>Lacking clearance of antigens from mucosal surfaces</li> <li>Autoreactive B cells due to impaired negative selection and regulation</li> <li>Reduced T regulatory function</li> <li>Reduced debris clearance</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>22q11 deletion syndrome (DiGeorge)</td> <td>2 to 5:10,000</td> <td>CID with syndromic features</td> <td> <ul> <li>Cardiac</li> <li>Abnormal facies</li> <li>Thymic hypoplasia</li> <li>Cleft palate</li> <li>Hypoparathyroidism</li> <li>Cognitive and speech problems</li> </ul> </td> <td>Variable, opportunistic infections</td> <td> <ul> <li>Cytopenia</li> <li>Endocrinopathies</li> <li>Arthritis</li> </ul> </td> <td> <ul> <li>Impaired T regulatory cell function and diversity</li> <li>Oligoclonal TCR repertoire</li> <li>Residual autoreactive T cells</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Wiskott-Aldrich syndrome (WAS)</td> <td>1:20,000</td> <td>CID with syndromic features</td> <td> <ul> <li>Microthrombocytopenia</li> <li>Eczema</li> </ul> </td> <td>Severe, viral, and bacterial opportunistic infections</td> <td> <ul> <li>Skin (eczema, atopic dermatitis)</li> <li>Cytopenia</li> <li>Vasculitis</li> <li>Kidney disease (nephritis, IgA nephropathy, glomerulonephritis)</li> <li>Arthritis</li> <li>IBD</li> </ul> </td> <td> <ul> <li>Defective T regulatory cell function</li> <li>Impaired lymphocyte migration and activation</li> <li>Loss of inhibitory signaling</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>CVID and CVID-like diseases including NFKB1 and NFKB2 deficiencies</td> <td>1 to 10:100,000</td> <td>Predominantly antibody deficiencies</td> <td> <ul> <li>Hypogammaglobulinemia</li> </ul> </td> <td>Recurrent infections</td> <td> <ul> <li>Cytopenia</li> <li>Endocrinopathies</li> <li>IBD</li> <li>Granuloma formation</li> <li>Arthritis</li> <li>Parenchymal lung disease</li> <li>Lymphoproliferation</li> <li>Lymphoma</li> <li>Alopecia</li> </ul> </td> <td> <ul> <li>BCR editing checkpoint, B cell maturation, and other signaling defects leading to residual autoreactive B cell clones</li> <li>Loss of inhibitory signaling</li> <li>Reduced T regulatory cell function</li> <li>Impaired T helper cell activity</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Combined immunodeficiencies (CID)*</td> <td>Unknown, estimated 1 to 5:100,000</td> <td>CID</td> <td> <ul> <li>Depending on subtype/genetic cause</li> </ul> </td> <td>Combined, variable severity</td> <td> <ul> <li>Cytopenia</li> <li>Endocrinopathies</li> <li>IBD</li> <li>Skin (eczema, rash, other)</li> <li>Lymphoproliferation</li> <li>Parenchymal lung disease</li> <li>Lymphoma</li> </ul> </td> <td> <ul> <li>Impaired T and T regulatory cell function and diversity</li> <li>Oligoclonal TCR repertoire</li> <li>Residual autoreactive T cells</li> <li>Hypersensitivity to persisting viral antigens</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Autoimmune lymphoproliferative syndrome (ALPS)</td> <td>Unknown, estimated &gt;1 to 5:100,000</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Increased TCR alpha/beta-positive CD4-CD8- DNT cells</li> </ul> </td> <td>Rare</td> <td> <ul> <li>Cytopenia</li> <li>Endocrinopathies</li> <li>Kidney disease (glomerulonephritis)</li> <li>Lymphoproliferation</li> <li>Lymphoma</li> </ul> </td> <td> <ul> <li>Apoptosis defect</li> <li>Immature and senescent T cell phenotype resulting in autoreactive T and B cells</li> <li>Impaired debris clearance</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Familial hemophagocytic lymphohistiocytosis (FHL), hemophagocytic lymphohistiocytosis (HLH)</td> <td>Unknown, estimated 1:50,000</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Hemophagocytosis</li> <li>Fever</li> <li>Hyperferritinemia</li> <li>Syndromes with or without hypopigmentation</li> </ul> </td> <td>EBV or other herpes viruses may be trigger</td> <td> <ul> <li>Cytopenia</li> <li>Lymphoproliferation</li> <li>Hemophagocytosis</li> <li>Neurologic symptoms (CNS infiltration)</li> </ul> </td> <td> <ul> <li>Uncontrolled cytokine and interferon-mediated macrophage activation due to impaired cellular cytotoxicity of T and NK cells</li> <li>Apoptosis defects</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>X-linked agammaglobulinemia (XLA)</td> <td>1:200,000</td> <td>Predominantly antibody deficiencies</td> <td> <ul> <li>Agammaglobulinemia</li> </ul> </td> <td>Bacterial, enteroviral</td> <td> <ul> <li>Cytopenia</li> <li>Endocrinopathies</li> <li>Skin (eczema, rash, vitiligo, alopecia, oral ulcerations, mucocutaneous candidiasis)</li> <li>IBD</li> </ul> </td> <td> <ul> <li>Unknown</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Chronic granulomatous disease (CGD)</td> <td>1 to 5:500,000</td> <td>Congenital defects of phagocyte number, function, or both</td> <td> <ul> <li>May mimic Crohn disease or lymphoproliferative disorders</li> <li>HLH</li> </ul> </td> <td>Bacterial (<em>Staphylococci</em>), fungal</td> <td> <ul> <li>Granuloma formation</li> <li>IBD</li> <li>Lymphoproliferation</li> </ul> </td> <td> <ul> <li>Ineffective and deregulated phagocyte activation, chemoattraction</li> <li>Impaired T regulatory function</li> <li>Defective clearance of apoptotic cells, hypersensitivity to bacterial antigens (neutrophil, NK mediated)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Hyperimmunoglobulin M syndromes (HIGM)</td> <td>1 to 2:500,000</td> <td>CID or predominantly antibody deficiencies</td> <td> <ul> <li><em>Cryptosporidium</em> infection</li> <li><em>Pneumocystis</em> pneumonia</li> <li>Sclerosing cholangitis</li> </ul> </td> <td>Bacterial and opportunistic infections</td> <td> <ul> <li>Cytopenia</li> <li>IBD</li> <li>Primary biliary cirrhosis</li> <li>Sclerosing cholangitis</li> </ul> </td> <td> <ul> <li>Disturbed T-B cell interaction</li> <li>Residual autoreactive B cells</li> <li>T cell-mediated hypersensitivity to parasitic antigens (<em>Cryptosporidium, Pneumocystis</em>)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Complement deficiencies<sup>¶</sup></td> <td>1 to 5:500,000</td> <td>Complement deficiencies</td> <td> </td> <td>Some have increased risk of neisserial infections</td> <td> <ul> <li>SLE</li> <li>Vasculitis</li> </ul> </td> <td> <ul> <li>Ineffective clearance of immune complexes, apoptotic cells, and debris</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>APECED</td> <td>1 to 10:1,000,000</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Ectodermal dystrophy</li> <li>21-hydroxylase autoantibodies</li> </ul> </td> <td>Candidiasis</td> <td> <ul> <li>Endocrinopathies</li> <li>Skin (eczema, rash, vitiligo, alopecia, oral ulcerations, mucocutaneous candidiasis)</li> </ul> </td> <td> <ul> <li>Central tolerance defect</li> <li>Anticytokine, enzyme-, and tissue-directed autoantibodies</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>XLP1 (SH2D1A deficiency)</td> <td>1 to 5:1,000,000</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Lymphoproliferation</li> <li>Hypo- or agammaglobulinemia</li> <li>HLH</li> <li>Lymphoma</li> </ul> </td> <td>EBV may be trigger</td> <td> <ul> <li>Lymphoproliferation</li> <li>Hemophagocytosis</li> <li>Lymphoma</li> <li>Cytopenia</li> </ul> </td> <td> <ul> <li>Disturbed T-B cell cross-talk</li> <li>Impaired T and NK cytotoxicity</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>CTLA4 haploinsufficiency (ALPSV)</td> <td>Unknown, estimated &lt;1:1,000,000</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Progressive loss of B cells</li> <li>Hypogammaglobulinemia</li> </ul> </td> <td>Upper and lower respiratory infections</td> <td> <ul> <li>IBD</li> <li>Granuloma formation</li> <li>Pneumonitis</li> <li>Cytopenia</li> <li>SLE</li> <li>Endocrinopathies</li> <li>Arthritis</li> <li>Neurologic disease (encephalitis, cerebellitis, CNS lymphoma)</li> <li>Lymphoproliferation</li> <li>Organ infiltration</li> <li>Malignancy</li> </ul> </td> <td> <ul> <li>T regulatory cell defect</li> <li>Impaired T cell help for B cells</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Activated PI3K-d syndrome</td> <td>Unknown, estimated &lt;1:1,000,000</td> <td>Predominantly antibody deficiency</td> <td> <ul> <li>T and B lymphoid nodules</li> <li>Bronchiectasis</li> <li>CVID-like</li> </ul> </td> <td>Respiratory tract infections, chronic EBV and CMV infection</td> <td> <ul> <li>Pneumonitis</li> <li>Cytopenia</li> <li>Lymphoproliferation</li> </ul> </td> <td> <ul> <li>Immature and terminal effector T cell phenotype</li> <li>Transitional B cells increased</li> <li>Lymphocyte sensitivity to activation-induced death</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>LRBA deficiency</td> <td>Unknown, estimated &lt;1:1,000,000</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Enteropathy</li> <li>ALPS/CVID-overlap syndrome</li> </ul> </td> <td>Bacterial and opportunistic infections</td> <td> <ul> <li>IBD</li> <li>Cytopenia</li> <li>Arthritis</li> <li>Myasthenia gravis</li> <li>Neurologic disease (encephalitis, cerebellitis, CNS lymphoma)</li> <li>Lymphoproliferation</li> </ul> </td> <td> <ul> <li>CTLA4-dependent T regulatory cell defect</li> <li>Impaired autophagy</li> <li>Autoreactive B cells</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>IPEX and IPEX-like syndromes</td> <td>Unknown, estimated &lt;1:1,000,000</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Early-onset enteropathy</li> <li>Type 1 diabetes mellitus</li> </ul> </td> <td>Combined, variable severity</td> <td> <ul> <li>IBD</li> <li>Endocrinopathies</li> <li>Cytopenia</li> <li>Skin (eczema, rash, vitiligo)</li> <li>Autoimmune hepatitis</li> </ul> </td> <td> <ul> <li>T regulatory cell deficiency or loss of function</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>XLP2 (XIAP deficiency)</td> <td>Unknown, estimated &lt;1:1,000,000</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Lymphoproliferation</li> <li>IBD</li> <li>HLH</li> </ul> </td> <td>EBV may be trigger</td> <td> <ul> <li>IBD</li> <li>Autoimmune hepatitis</li> <li>Lymphoproliferation</li> <li>Cytopenia</li> </ul> </td> <td> <ul> <li>T cell apoptosis and activation-induced cell death</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>CD27 deficiency</td> <td>Unknown, estimated &lt;1:1,000,000</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Hypogammaglobulinemia</li> <li>Lymphoma</li> </ul> </td> <td>EBV may be a trigger</td> <td> <ul> <li>Lymphoproliferation</li> <li>Hemophagocytosis</li> <li>Lymphoma</li> <li>Cytopenia</li> </ul> </td> <td> <ul> <li>Impaired antigen-activated T and B cell expansion and memory development</li> <li>Impaired NK function</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>ITK deficiency</td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Hodgkin (and rarer non-Hodgkin) lymphoma</li> </ul> </td> <td>EBV may be trigger</td> <td> <ul> <li>Lymphoproliferation</li> <li>Lymphoma</li> <li>Cytopenia</li> </ul> </td> <td> <ul> <li>Skewed CD4 T cell differentiation</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Type 1 interferonopathies</td> <td>Unknown</td> <td>Autoinflammatory disorders</td> <td> <ul> <li>Progressive encephalopathy</li> </ul> </td> <td> </td> <td> <ul> <li>SLE</li> <li>Cytopenia</li> <li>Vasculopathy</li> </ul> </td> <td> <ul> <li>Impaired cellular nucleic debris clearance</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Early-onset inflammatory bowel disease syndromes</td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td> </td> <td>Respiratory infections</td> <td> <ul> <li>IBD</li> <li>Arthritis</li> <li>Lymphoma</li> </ul> </td> <td> <ul> <li>Lacking responses to immune regulatory interleukins</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>CMC/STAT1 gain of function</td> <td>Unknown</td> <td>Defects in innate immunity</td> <td> <ul> <li>CMC</li> </ul> </td> <td>Fungal, bacterial, mycobacterial, herpesvirus infections</td> <td> <ul> <li>Endocrinopathies</li> <li>Pneumonitis</li> <li>Cytopenia</li> </ul> </td> <td> <ul> <li>Impaired development of IL-17-producing T cells</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>STAT3 gain of function</td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Early onset</li> <li>IPEX-like</li> </ul> </td> <td> </td> <td> <ul> <li>IBD</li> <li>Endocrinopathies</li> <li>Cytopenia</li> <li>Pneumonitis</li> <li>Autoimmune hepatitis</li> <li>Lymphoproliferation</li> </ul> </td> <td> <ul> <li>Increased T cell differentiation towards IL-17 production</li> <li>Perturbed T regulatory cell function</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>SOCS1 haploinsufficiency</td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Early-onset severe multiorgan autoimmunity and autoinflammation</li> </ul> </td> <td>Recurrent bacterial infections</td> <td> <ul> <li>Cytopenia</li> <li>Lymphopenia</li> <li>Neutropenia</li> <li>SLE</li> <li>Thyroiditis</li> <li>Eczema</li> <li>Psoriasis</li> <li>Arthritis</li> <li>Hepatitis</li> <li>Nephritis</li> </ul> </td> <td> <ul> <li>Reduced T and switched memory B cells</li> <li>Increased interferon I/II signature and STAT1 activation</li> </ul> </td> </tr> <tr> <td>IKAROS gain of function</td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td> <ul> <li>Multiorgan autoimmunity</li> </ul> </td> <td> </td> <td> <ul> <li>Endocrinopathies</li> <li>Colitis</li> <li>Allergy</li> <li>Cytopenia</li> <li>Lymphoproliferation</li> <li>IgG4-positive plasma cell expansion</li> </ul> </td> <td> <ul> <li>Regulatory T cell defect due to IKAROS-mediated gene activation/regulation</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>IEI: inborn error of immunity; PID: primary immunodeficiency; IUIS: International Union of Immunological Societies; IgA: immunoglobulin A; CVID: common variable immunodeficiency; CID: combined immunodeficiency; TCR: T cell receptor; IBD: inflammatory bowel disease; NFKB: nuclear factor kappa B; SLE: systemic lupus erythematosus; BCR: B cell receptor; DNT: double-negative T; EBV: Epstein-Barr virus; CNS: central nervous system; NK: natural killer; HLH: hemophagocytic lymphohistiocytosis; APECED: autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; XLP: X-linked lymphoproliferative disorder; SH2D1A: SH2 domain protein-1A; CTLA4: cytotoxic T lymphocyte-associated protein 4; ALPSV: autoimmune lymphoproliferative syndrome type 5; PI3K-d: phosphoinositide-3 kinases delta; CMV: cytomegalovirus; LRBA: lipopolysaccharide-responsive beige-like anchor; IPEX: immune dysregulation, polyendocrinopathy, and enteropathy, X-linked; XIAP: X-linked inhibitor of apoptosis protein; ITK: interleukin 2-inducible T cell kinase; CMC: chronic mucocutaneous candidiasis; STAT: signal transducer and activator of transcription; IL: interleukin; SOCS1: suppressor of cytokine signaling 1; IgG4: immunoglobulin G4.</p>
<p>* Including Omenn syndrome, leaky or hypomorphic severe combined immunodeficiency (SCID), and defects in various T cell surface receptors, lymphocyte structural, or T-B cell activation or signaling, which are usually less severe than SCID. Some of these disorders are also listed separately in this table because they belong to multiple categories of PID.</p>
¶ Excluding hereditary angioedema.</div><div class="graphic_reference">References:
<ol>
<li>Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473.</li>
<li>Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood 2002; 99:2694.</li>
<li>Todoric K, Koontz JM, Mattox D, Tarrant TK. Autoimmunity in immunodeficiency. Curr Allergy Asthma Rep 2013; 13:361.</li>
<li>Grimbacher B, Warnatz K, Yong PF, et al. The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects. J Allergy Clin Immunol 2016; 137:3.</li>
<li>Fischer A, Provot J, Jais JP, et al. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol 2017; 140:1388.</li>
</ol></div><div id="graphicVersion">Graphic 104453 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
